Biotechnology
Bestqool Unveils Four-Wavelength Pro Series and Second-Gen Mobile Stand at Original Price
NEW YORK, Feb. 20, 2025 /PRNewswire/ -- In a recent announcement, Bestqool is
upgrading both the Pro100 and Pro200 to the four-wavelength configuration (630
nm, 660 nm, 850 nm, 940 nm) as the Pro 300
2025-02-21 01:09
2688
FIRST AND ONLY TREATMENT FOR CHRONIC HYPOPARATHYROIDISM APPROVED IN AUSTRALIA
* YORVIPATH® (palopegteriparatide) is now registered by the Therapeutic Goods Administration (TGA) for the treatment of chronic hypoparathyroidism in adults1 * First-in-class novel PTH replacement therapy * Australia becomes the first country to obtain Marketing Authorisation for YORVIPATH s...
2025-02-21 00:01
2878
Harbour BioMed and Insilico Medicine Achieve Strategic Collaboration to Advance AI-Driven Antibody Discovery and Development
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 20, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immunology and oncology, a...
2025-02-20 15:31
2574
Nona Biosciences Announces Licensing Agreement with the University of Alabama at Birmingham to Support B Cell Development Research
CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to I™), today announced a licensing agreement with theUniversity of Alabama at Birmingham (UAB) to support their research in B cell development. Und...
2025-02-20 09:21
2264
Brexogen and BMI Korea Enter Strategic Technology Transfer Agreement for Exosome Therapeutics
Out-licenses BxC-I17e, Exosome-Based Therapeutics for New Indications
KRW 3 Billion Non-Refundable Upfront Payment + Milestone Payments +
Double-Digit Percentage Royalties
SEOUL, South Korea, Feb. 19, 2025 /PRNewswire/ -- Brexogen
2025-02-19 21:00
2237
Biosion, Inc. Appoints Kedan Lin, Ph.D., as Chief Development Officer and President of Biosion US
NEWARK, Del. and NANJING, China, Feb. 19, 2025 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical-stage biotechnology company, is pleased to announce the appointment ofKedan Lin, Ph.D., as Chief Development Officer and President of Biosion US. With over two decades of expertise in biote...
2025-02-19 19:39
3053
WuXi Biologics Awarded Platinum Medal by EcoVadis Sustainability Rating for Second Consecutive Year
* Ranked among the top 1% of more than 150,000 companies across 185 countries * Trusted by global partners for strong sustainability commitment * Recognized as a leader in Green CRDMO, driving innovation for a healthier future SHANGHAI, Feb. 18, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"...
2025-02-18 17:00
2802
SBTi Verifies GenScript Biotech Corp's Carbon Emission Reduction Goals, Marking a Major Sustainability Milestone!
PISCATAWAY, N.J., Feb. 18, 2025 /PRNewswire/ -- GenScript Biotech Corp, a global leader in life sciences R&D and manufacturing services, today announced that it is committing to aggressive carbon emission reduction targets. These targets have been verified by the Science Based Targets initiative ...
2025-02-18 15:27
2118
CJ Bioscience to Present Preclinical Data on Inflammatory Bowel Disease Pipeline Candidate CJRB-201 at 'ECCO 2025'; Clinical Entry Targeted for 2026
* 'CJRB-201', a proprietary strain of Faecalibacterium with potent its anti-inflammatory effects, has demonstrated the strongest induction of regulatory T cells (Tregs) among analyzed strains. * Preclinical studies in multiple animal models confirm significant improvements in key disease indi...
2025-02-18 15:00
2510
IASO Bio Announces Acceptance of New Drug Application for Equecabtagene Autoleucel (FUCASO) by the Hong Kong Department of Health
SHANGHAI and NANJING, China and SAN JOSE, Calif., Feb. 14, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that theHong Kong ...
2025-02-14 22:30
4548
Bambusa Therapeutics Raises Approximately $90 Million in Series A Financing to Advance Next-generation Bispecific Antibodies for Immunology & Inflammation Diseases
BOSTON, Feb. 14, 2025 /PRNewswire/ -- Bambusa Therapeutics, Inc. (Bambusa), a biotechnology company developing bispecific antibodies for immunological and inflammatory (I&I) disorders, today announced the successful completion of its oversubscribed Series A financing of approximately $90 million....
2025-02-14 21:56
3522
Harbour BioMed Announces Business Progress and Update
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 13, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology, ...
2025-02-14 12:08
3893
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
* Hanmi Pharmaceutical Global Business Headquarters Accelerates Expansion into Canadian and US Markets, Strengthening Collaboration with Distribution Partner McKesson * Introducing 'Countmate': A Customized Solution for Canadian and American Pharmacists Seeking Advanced Vial Preparation Techn...
2025-02-14 08:35
2888
Accropeutics Announces First Patient Dosed in Phase Ib Study of RIPK2 Inhibitor AC-101
NEW YORK, Feb. 13, 2025 /PRNewswire/ -- Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patien...
2025-02-13 18:53
1853
Restore Vision Announces First Patient Dosed in Phase I/II Clinical Trial of RV-001 for Gene-Agnostic Retinitis Pigmentosa
* The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. * RV-001 starting dose was generally well tolerated in this open-label trial. * RV-001 a gene-agnostic approach for RP patients. TOKYO, Feb. 13, 2025 /PRNewswire/ -- Restore Vision Inc., a clinical-stage biotechnology...
2025-02-13 15:00
1847
DAAN Biotherapeutics Signs Antibody Exclusive Licensing Agreement with LigaChem Biosciences for ADC (Antibody-Drug Conjugate) Therapeutic Development
SEOUL, South Korea, Feb. 13, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-cell receptor (TCR)- based therapies, has signed an exclusive licensing agreement with LigaChem Biosciences for a novel tumor-targeting antibody to advance the ...
2025-02-13 13:40
1759
Akeso Announced Enrollment of First Patient in Phase 3 Trial of Cadonilimab for Consolidation Therapy After Concurrent or Sequential Chemoradiotherapy in NSCLC
HONG KONG, Feb. 12, 2025 /PRNewswire/ -- Akeso, Inc. (9926. HK) ("Akeso" or the "Company") announced the recent completion of the first patient enrollment in the Phase 3 randomized, double-blind, multicenter clinical trial (COMPASSION-30/AK104-309) for its independently developed PD-1/CTLA-4 bis...
2025-02-13 09:26
2109
OnCusp Therapeutics Receives FDA Fast Track Designation for CUSP06 for the Treatment of Platinum-Resistant Ovarian Cancer
PRINCETON, N.J., Feb. 12, 2025 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical stage biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients, today announced that the U.S. Food and Drug Administration (...
2025-02-12 21:00
2194
Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal
Confirms the utility of the 10 mg daily oral dose of Xanamem being studied in late-stage clinical trials in Alzheimer's disease and major depressive disorder SYDNEY, Feb. 12, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the publication of its most recent peer-reviewed...
2025-02-12 21:00
2297
Samsung Biologics recognized for leadership band in water security
- Company receives leadership status and A- rating for efficient water resources management - Recognition reflects Samsung Biologics' commitment to water security and implementing sustainable practices across operations INCHEON, South Korea, Feb. 12, 2025 /PRNewswire/ -- Samsung Biolo...
2025-02-12 20:00
2778
Week's Top Stories
Most Reposted
Visa partners with Laufey to spread the magic of travel in Asia Pacific; to be Official Payment Partner for Laufey: A Matter of Time Tour
[Picked up by 309 media titles]
2026-03-04 12:35
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 291 media titles]
2026-03-03 15:49
Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 290 media titles]
2026-03-02 09:00
COL and NASDAQ-Listed BeLive Holdings Unveil World's First "Microdrama in a Box" in Headline Hong Kong FILMART 2026 Launch
[Picked up by 287 media titles]
2026-03-05 17:14
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
10701
